Skip to main content
Grafa
Health
McKesson to acquire Precision Medicine Group for $2.25 billion
Image for illustrative purposes only. Not a real photo.

McKesson to acquire Precision Medicine Group for $2.25 billion

Share
  • McKesson (NYSE:MCK) agreed to acquire Precision Medicine Group for approximately $2.25 billion.
  • The acquisition expands McKesson’s oncology and multispecialty clinical research and commercialization capabilities.
  • Precision Medicine Group will join McKesson’s Oncology & Multispecialty segment after closing.

McKesson (NYSE:MCK) agreed to acquire Precision Medicine Group for approximately $2.25 billion, adding clinical research and biopharma commercialization services to its oncology and multispecialty operations.

Precision Medicine Group provides services for biotechnology and pharmaceutical companies, including biomarker intelligence, laboratory services, global clinical research, market access consulting, and commercialization support.

Following completion of the transaction, Precision Medicine Group will report within McKesson’s Oncology & Multispecialty segment, subject to customary closing conditions including regulatory clearances.

McKesson stated that Precision Medicine Group’s capabilities are expected to expand its clinical research and commercialization services, while Precision Medicine Group said the combination will provide broader support for biopharma customers.

McKesson operates healthcare distribution, technology, and services businesses, while the Precision Medicine Group acquisition expands its presence in oncology services and pharmaceutical development support.

Frequently asked questions